WO2011017903A1

WO2011017903A1 - Umbilical region treat device

Info

Publication number: WO2011017903A1
Application number: PCT/CN2010/001090
Authority: WO
Inventors: 杨孟君
Original assignee: Yang Mengjun
Priority date: 2009-08-14
Filing date: 2010-07-20
Publication date: 2011-02-17
Also published as: CN101991909A

Abstract

The invention discloses a human umbilical region treat device, which is composed of a treatment box (4) and a fixture (5) assorted to the treatment box. Said treatment box includes a cover (2) and a box body (3), the medicine that is information stuffing block or stuffing bag made of no attenuation information material is set in the box body. There are air vents on the treatment box. The invention substitutes traditional taking medicine method or means of invasive treatment, prevention of diseases, cosmetology and health care by new medicine delivery of information superconducting function, which can reach or exceed the effective rate of medicine treatment. The device is simple to operate and facilitate family self-rehabilitation. No chemical substances enter the body when the device is used. The device prevents toxic and side effect caused by the medicine in body, thus medical resources are saved, and environmental pollution from pharmaceutical industry is reduced.

Description

Umbilical treatment device

Technical field

The invention belongs to a medical device, and particularly relates to a treatment device for a human umbilicus.

Background technique

Umbilical therapy is a commonly used medical technique. Existing umbilical therapy techniques or patents are made into traditional dosage forms such as paste, scatter, pills, cream, etc., applied to the umbilicus, or applied to the umbilicus to apply certain physical stimuli, such as moxibustion, needles. Sting, hot ironing, cupping, etc., to treat the disease. The transdermal patch invented in recent years is also used as a navel treatment. These patents or techniques have the common feature of either absorbing the drug through the umbilical navel skin and allowing the drug to enter the body; or applying some physical stimulation to the navel of the umbilicus to modulate the body through skin acupoint stimulation. The defects of these navel therapy techniques are: Whether the drug is applied directly to the navel or directly exerts physical stimulation on the navel, it has bad stimulation or injury to the navel skin; the clinical curative effect is not ideal, and can not be used as the main means of treating diseases; Sticking to the navel, the drug is absorbed into the human body through the navel, and the toxic side effects of the drug are still unavoidable.

Summary of the invention

The object of the present invention is to propose a new and innovative umbilical treatment device that does not directly contact the human body in view of the deficiencies of the current navel therapy technology.

The object of the invention is achieved by the following technical solutions:

An umbilical treatment device comprising a treatment box 4 and a fixture 5 for use with the treatment box 4, and a venting hole 6 on the treatment box 4, wherein the treatment box 4 is a carrier, To achieve a new mode of administration of bioinformation.

The treatment box 4 comprises a lid 2 and a box 3, and the box 3 is provided with an information packing block or a packing bag 1.

The information filler block or the information filler package 1 is made of a non-attenuating information material, and the non-attenuating information material refers to a drug having pharmacological activity and treating diseases for a new production period of less than one year.

In the umbilical treatment device of the present invention, the information filler block or the information in the information filler package 1 includes a physiological function for regulating human or animal diseases for the purpose of treating and/or preventing human or animal diseases,

] Or a single compound, biological product or composition that acts on the human or animal body for conception, contraception or beauty.

In the umbilical treatment device of the present invention, the information filling block 1 is pressed by using a relevant mold, and after the medicine is directly loaded into the mold, it is pressed into a shape by a press; or the adhesive is added to the medicine. after mixing into a mold after press molding with a press fingers; the filler information packet 1 with a pharmaceutical excipient added, mixed sufficiently charged 50n _m - packet object made of microporous material aperture 20 _Um air bags.

In the umbilical treatment device of the present invention, in a ratio of 90-99% of the total weight of the drug relative to the information filler block, and 1-10% of the total weight of the adhesive relative to the information filler block, at normal temperature and pressure After mixing, after loading into the mold, press the 10-100 ton press to make the block packing material, ie, the information packing block 1; or take the medicine, add the auxiliary material, mix well at normal temperature and pressure or granulate and dry, and dispense with the filling machine. Into the 50nm-20 pore size microporous material venting bag, that is, the information packing package 1.

In the umbilicus treatment device of the present invention, the vent hole 7 is disposed on the lid 2 or at the bottom of the casing 3.

In the umbilical treatment device of the present invention, the venting hole 7 has a diameter of 0. 01-0. 5cm. In the umbilical treatment device of the present invention, the fixture 5 includes a therapeutic box 4 Or a rope, belt, bag, rack, paste or tape that is fixed to the umbilicus of the human body.

In the umbilical treatment device of the present invention, the lid 2 is connected to the casing 3 by screwing or the socket is clamped or the adhesive is adhered.

The beneficial effects of the invention are:

1. With the new information superconducting method, no medicinal chemicals enter the human body, which can avoid the side effects of drugs in the body.

2, no direct contact with the skin, no skin irritation and damage.

3, the clinical treatment effect is significant, can achieve or exceed the effectiveness of drug treatment.

4. The umbilical unit can be reused many times within 3 years, reducing the waste of drugs in conventional treatment, saving medical resources, and reducing environmental pollution in the pharmaceutical industry, which is conducive to environmental protection. 5, easy to use, convenient for family self-healing treatment.

DRAWINGS

Figure 1 is a schematic view of the treatment box of the present invention (the lid is open);

Fig. 2 is a schematic view showing the treatment box and the fixture of the present invention (the lid is closed).

1. Information packing block or packing package

2, cover

3, the box

4, the treatment box

5, fixtures

6, venting holes

7, wearing a hole

detailed description

Referring to Figures 1 and 2, an umbilical treatment device consists of a treatment box 4 and a fixture 5 for use with the treatment box 4. The treatment box 4 is composed of a lid 2 and a box body 3, in which an information packing block or packing bag 1 is mounted, and an information packing block or packing bag 1 is made of a non-attenuating information material, the non-attenuating information The material refers to a pharmacologically active drug that has been produced for no more than one year. The fixture 5 includes a cord, a belt, a bag, a shelf, a sticker or a tape that can suspend or secure the treatment cartridge 4 to the umbilicus of the human body. The fixture 5 is used to hang the treatment box 4 or directly attached to the umbilicus of the human body. The fixture 5 can be integrated with the treatment box 4 or can be placed separately from the treatment box 4, but used in conjunction with each other. In Fig. 1, the casing 3 is provided with a perforation hole 7. In the embodiment shown in Fig. 2, the fixture 5 is a belt which is worn on the perforation hole 7 and then tethered to the human body. A venting hole 6 is disposed on the treatment box 4. The best way is to vent the venting hole 6 on the lid 2 and the bottom of the box body 3 to ensure that the inside and outside of the treatment box 4 are ventilated, and the medicine information in the box 4 is treated. Superconducting emission. The vent hole 6 has a pore diameter of 0.01 to 0.5 cm.

The treatment box 4 is made of a plastic, ceramic or metal-formable material, and the shape of the treatment box 4 can be various shapes. After the information packing block or packing bag 1 is placed in the treatment box 3, the treatment box cover 2 is closed. The treatment box cover 2 can be connected to the treatment box body 3 by screwing or the socket is fastened or the adhesive is adhered.

The drug information filler block or filler package 1 used is made of a non-attenuating information material, i.e., a drug having pharmacological activity. The medicaments are for the treatment and prevention of human and animal diseases, for the purpose of regulating the physiological functions of humans or animals or for the treatment of a single compound, biological product and composition of the human or animal for conception or contraception and beauty. The drugs are approved for use by the national government drug administration, and are in compliance with national pharmacopoeia standards or national and other standards. The information filling block 1 is pressed by using a related mold, and the medicine is directly loaded into a mold and then pressed into a shaped object by a press, or the medicine is added to a certain proportion of a binder, such as sodium carboxymethyl cellulose, and then mixed. After entering the mold, it is pressed into a tangible block by a press. The information filler package 1 is a small bag object prepared by adding a suitable excipient with a drug and mixing it into a gas-permeable bag of a microporous material having a pore diameter of 50 nm to 20 μm.

The production process of the invention is: 1 according to the structural requirements of the present invention, the conventional processing process of the treatment box 4, the fixture 5; 2 take the attenuation-free information material 90-99% by weight, the binder 1-10% by weight, at normal temperature and pressure Under mixing, the mold is filled into a block with a 10-100 ton press, that is, the information packing block 1; or the non-attenuating information material is added, an appropriate amount of the auxiliary material is added, and the mixture is sufficiently mixed under normal temperature and normal pressure, or granulated and dried, The dispensing machine is filled into a 50nm-20um pore size microporous material venting bag to form an information packing package 1; the non-attenuating information material is a pharmacologically active drug newly produced without leaving the factory for more than one year, that is, for treatment and prevention. Human and animal diseases, a single compound, biological product, and composition that purposely regulates human or animal physiology or acts on the human or animal for conception or contraception and beauty, and meets appropriate national standards. 3 Put the information packing block or packing bag 1 into the treatment box 4, cover The treatment box cover 2 is fixed and fixed firmly; 4 the fixture 5 is mounted on the treatment box 4; 5 The treatment box 4 is placed in a sealed box or bag which is completely airtight and sealed and stored dry.

The method of use of the invention is: opening a sealed box or sealed bag which is completely airtight, taking out the treatment box 4, pulling apart the suspension or the fixture 5, placing the treatment box 4 on the umbilicus of the human body, and making the treatment box 4 have the venting hole 6 The bottom or the lid 2 with the venting opening 6 faces the umbilicus skin, and is suspended or fixed in the umbilicus of the human body during the clinically prescribed treatment time. At the end of the treatment time, the treatment box 4 is removed and placed completely Sealed in a gas-tight sealed box or sealed bag.

The use of the present invention is to treat and prevent human and animal diseases, and to be used in human health and beauty. The "%" described in the following examples is "% by weight".

Example 1

The treatment box 4 is injection molded with an injection mold and ABS plastic material. Designed to be oblate, 10 cm in diameter, 1.5 cm in height, 1.2 cm in height, and a plurality of vent holes 6 having a diameter of 0.1 cm (the venting holes 6 are provided at the bottom of the casing 3 of the treatment box 4) on the treatment box 4, designed The suspension belt is provided with a hole 7.

Take no attenuation information material metformin hydrochloride 70%, glimepiride 28%, binder carboxymethyl cellulose sodium 2%, mixed under normal temperature and pressure, into the mold, pressed with a 30-ton press to make flat circular information The packing block 1 has a diameter of 9.5 cm, a center height of 1.3 cm, and a peripheral height of 1.0 cm.

The information packing block 1 is placed in the treatment box 4, the treatment box cover 2 is covered, and the treatment box cover 2 is firmly adhered to the treatment box body 3 with a urethane adhesive, 502 glue. Put the purchased nylon strap, the length of the nylon strap hanging from the neck of the human body to the height of the umbilicus, and insert it into the treatment box.

To treat diabetes, take out the treatment box 4 when using, pull out the suspension strap, and hang the treatment box 4 in the umbilicus of the human body, so that the bottom of the treatment box 4 has the venting hole 6 facing the umbilicus skin, and each suspension treatment is 4-5 hours. After the treatment is finished, the treatment box 4 is taken out, placed in a sealed package for recharging, and then opened again after the next use, and then placed in a sealed package for charging after use. Valid for 3 years. The invention is used for treating 84 cases of type 2 diabetes, and the effect is good.

Materials and Methods

1.1 General Information 84 patients were clinically diagnosed with diabetes, and were diagnosed with type 2 diabetes using the 1999 WHO diagnostic criteria for diabetes. Among them, 46 males and 38 females, aged 47-62 years, with an average age of 64±7.6 years. Fasting blood glucose <8.3 ₁₁ 111101/1^ in 5 cases, 8.3-l l.lmmol/L in 23 cases, >l l.lmmol L in 14 cases. All cases had no obvious liver and kidney damage and cardiovascular complications, and there was no stress, such as infection, surgery or pregnancy.

1.2 treatment method for diabetes information superconducting umbilical therapy device treatment, once a day, 4 hours each time, a total of 4 weeks of treatment, before and after treatment, blood ventral blood glucose (FPG), postprandial 2h blood glucose (2hPG), glycosylated hemoglobin (GHbAl), cholesterol (Tch), triglyceride (TG) 1 time. During the treatment, the patient was instructed for diet control and exercise therapy, and hypoglycemic drugs were not used. The changes in the test indicators and adverse reactions were observed after 4 weeks.

2. Results

No adverse reactions occurred during the treatment. The test indicators before and after treatment are shown in the table 1.

Table 1 Comparison of test indicators before and after treatment (X soil S)

FPG 2Hpg GHbAl TG Tch

(Draw ol/L) (mmol/L) (%) (mmol/L) (mmol/L) 10.24±4.45 before treatment 15.61 ± 3.42 11.00± 1.65 5.88 ± 1.75 1.98 ±0.27 6.61 ± 1.55 after treatment 8.25 ± 1.59 7.91 ± 1.53 4.53 ± 1.03 1.71 ± 0.12 P value <0.05 <0.01 <0.05 <0.05 <0.05

Embodiment 2 The treatment box 4 is designed to have an oblate shape, a diameter of 10 cm, a center height of 1.5 cm, and a peripheral height of 1.2 cm. The treatment box cover 2 is designed with a plurality of vent holes having a diameter of 0.1 cm, and the treatment box 4 is provided with a suspension belt and a hole 7 . It is injection molded by injection molding process ABS plastic material. Take 10% of melanin without attenuation information, 20% of left clone, 50% of extract of Wujiapi, 20% of tourmaline powder with particle size of 100 nm, mix well at normal temperature and pressure, granulate, and charge 50nm-20um The pore material of the microporous material is ventilated in a circular bag, and the bag mouth is sealed, that is, the information packing bag 1 is prepared.

The information filling is packaged into the treatment box 4, the treatment box cover 2 is covered, and the treatment box cover 2 is adhered to the treatment box body 3 with a urethane adhesive, 502 glue. Hang the purchased nylon strap to the neck of the human body to the height of the umbilicus. The length of the nylon tape is inserted into the treatment box. 4 Wearing a hole 7 knotted. That is, an insomnia umbilical treatment device is prepared. When in use, the treatment box 4 is hung in the umbilicus of the human body, and the treatment box cover 2 with the venting hole 6 is placed against the umbilicus skin, and is suspended for one hour before going to bed, and can be used for sleeping for one hour each time. After the treatment, The treatment box 4 is removed and stored in a sealed package.

The invention is used for treating 50 cases of senile insomnia, all of which are effective, and the clinical data are as follows:

1. Clinical data

1.1 Case selection 1 elderly, age 60 years; 2 severe insomnia, night sleep 4 hours; 3 have taken the following drugs alone more than 3 kinds, sleep extended for 1 hour: stability, Shule and stability, Zaoren capsule, Qiye Shenan tablets , Shenqi Schisandra tablets and other tranquil sedative drugs.

1.2 General information: 50 patients in the treatment group, including 37 males and 13 females; aged 61-83 years, mean 73 years old. 45 cases were compared, including 35 males and 10 females; aged 60-80 years, mean 74 years old.

1.3 treatment: treatment group: use insomnia umbilical treatment device, hanging in the umbilicus, 1 hour before going to bed, 1 night; control group: diazepam 5mg. 0.5-1 hour before bedtime orally 1 time.

1.4 Efficacy criteria. Very significant: After treatment, sleep at night for 7 hours; Significantly: 6 hours; Effective: 5 hours; Invalid: <5 hours.

2, the result

All cases are valid on the same day as the drug is administered. The effective rate of the treatment group was significantly higher than that of the control group. There are very significant differences, the treatment results are shown in Table 2.

Table 2 Comparison between the treatment group and the control group (%) n Very effective, effective and effective treatment group 50 23 (46) 20 (40) 6 (12) 1 (2) Control group 45 10 (22.2) 15 (33.3) 14 (31.1) 6 (13.3) The treatment group and the control group were tested by X ² , X ² = 137.123 ΡΟ.005.

Claims

Claim

An umbilical treatment device, characterized in that it consists of a treatment box (4) and a fixture (5) for use with the treatment box (4), and is arranged on the treatment box (4) Venting hole

(7); The therapeutic device is a novel administration method in which the treatment box (4) is used as a carrier to realize bioinformation administration.

2. The umbilical treatment device according to claim 1, characterized in that: the treatment box (4) comprises a lid (2) and a box (3); and an information filler is contained in the box (3) Block or information packing package (1).

3. The umbilical treatment device according to claim 2, wherein: the information filler block or the information filler package (1) is made of a non-attenuating information material, and the non-attenuation information material refers to a new production factory. No more than 1 year of pharmacologically active, symptomatic treatment of the corresponding drug.

The umbilical treatment device according to claim 3, characterized in that: the information filler block or the information in the information filling package (1) comprises regulating the human body for treating and/or preventing human or animal diseases and purposes. Or a single compound, biological product or composition that acts on the physiology of an animal, or on a human or animal body for conception, contraception or beauty.

The umbilical treatment device according to claim 3, wherein: the pressing of the information filler block (1) is performed by using a relevant mold, and directly pressing the medicine into the mold, and pressing the shape into a shape by a press; Alternatively, the binder may be added to the drug, mixed and put into a mold, and then pressed into a shape by a press; the information filler package (1) is added with a drug, and mixed sufficiently to be loaded into a micrometer having a pore diameter of 50 nm to 20 μm. A small bag of objects made of breathable bags of hole material.

6. The umbilical treatment device according to claim 5, characterized in that: according to the ratio - 90-99% of the total weight of the drug relative to the information filler block, and 1 of the total weight of the adhesive relative to the information filler block -10%, mixed under normal temperature and normal pressure, after being loaded into the mold, press 10-100 tons of press to make block packing material (1); or take medicine, add auxiliary material, mix well under normal temperature and pressure Or granulation drying, use a dispenser to fill the 50 _nm -20 _U m pore size microporous material venting bag, that is, the information packing package (1).

7. The umbilicus treatment device according to claim 1, wherein: said venting hole (7) Layout on the lid (2) or at the bottom of the box (3).

The umbilical treatment device according to claim 1, characterized in that the venting hole (7) has a pore diameter of 0.01-0.5 cm.

The umbilical treatment device according to claim 1, characterized in that the fixing object (5) comprises a rope, a belt, a bag, a frame, and a paste which can suspend or fix the treatment box (4) in the umbilicus of the human body. Or tape.

The umbilical treatment device according to claim 1, characterized in that the lid (2) is connected to the casing (3) in a screwing manner or the socket is clamped or the adhesive is adhered.